耳迷走神经刺激治疗活动性类风湿关节炎的随机双盲假刺激对照临床试验
这项随机双盲假刺激对照试验纳入113例对传统合成改善病情抗风湿药应答不足且未使用过生物制剂或靶向合成改善病情抗风湿药的活动性类风湿关节炎患者,1:1随机接受耳迷走神经刺激或假刺激。第12周ACR20应答率主动刺激组25.0%对假刺激组26.9%,差异无统计学意义;DAS28-CRP变化两组间无显著差异,HAQ-DI变化两组间P=0.044。结论认为耳迷走神经刺激未显著改善类风湿关节炎疾病活动度。
要点
- 第12周ACR20应答率主动刺激组25.0%对假刺激组26.9%,差异-1.9(95%CI -18.8, 14.9,P=0.823)。
- DAS28-CRP最小二乘均值变化主动刺激组-0.95±0.16对假刺激组-0.66±0.16,P=0.201。
- HAQ-DI变化主动刺激组-0.19±0.06对假刺激组-0.02±0.06,P=0.044。
核心结论
- 耳迷走神经刺激未显著改善类风湿关节炎疾病活动度。
- 若未来探索其他方式的迷走神经刺激治疗类风湿关节炎,需要更大规模的对照研究来了解其效用。
研究设计与样本
- 随机双盲假刺激对照试验,纳入18至75岁活动性类风湿关节炎患者,这些患者对传统合成改善病情抗风湿药应答不足且未使用过生物制剂和/或靶向合成改善病情抗风湿药。
- 所有患者均接受耳迷走神经刺激器,按1:1随机分为主动刺激组或假刺激组。
- 主要终点为第12周达到美国风湿病学会20%改善标准(ACR20)的患者比例。
- 次要终点包括28关节疾病活动度评分(基于C反应蛋白,DAS28-CRP)和健康评估问卷-残疾指数(HAQ-DI)的平均变化。
- 共纳入113例患者(平均年龄54岁;女性82%),101例(89.4%)完成第12周。
主要发现
- 第12周ACR20应答率主动刺激组为25.0%,假刺激组为26.9%,差异为-1.9(95%CI -18.8, 14.9,P=0.823)。
- DAS28-CRP最小二乘均值±标准误变化主动刺激组为-0.95±0.16,假刺激组为-0.66±0.16(P=0.201)。
- HAQ-DI最小二乘均值±标准误变化主动刺激组为-0.19±0.06,假刺激组为-0.02±0.06(P=0.044)。
- 17例患者(15%)发生不良事件,均为轻度或中度。
临床怎么用
- 原文结论认为耳迷走神经刺激未显著改善类风湿关节炎疾病活动度;若未来探索其他方式的迷走神经刺激治疗类风湿关节炎,需要更大规模的对照研究来了解其效用。
局限性
- 若未来探索其他方式的迷走神经刺激治疗类风湿关节炎,需要更大规模的对照研究来了解其效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Preliminary evidence suggests that vagus nerve stimulation (VNS) may have some benefit in patients with rheumatoid arthritis (RA); however, prior studies have been small and/or uncontrolled; this study aimed to address that gap. METHODS: This randomized, double-blind, sham-controlled trial enrolled patients aged 18 to 75 years with active RA who had failed conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and were naïve to biologic and/or targeted synthetic DMARDs. All patients received an auricular vagus nerve stimulator and were randomized 1:1 to active stimulation or sham. The primary endpoint was the proportion of patients achieving 20% improvement in American College of Rheumatology criteria (ACR20) at week 12. Secondary endpoints included mean changes in disease activity score of 28 joints with C-reactive protein (DAS28-CRP) and Health Assessment Questionnaire-Disability Index (HAQ-DI). RESULTS: A total of 113 patients (mean age 54 years; 82% female) enrolled, and 101 patients (89.4%) completed week 12. ACR20 response at week 12 was 25.0% for active stimulation versus 26.9% for sham (difference vs. sham, -1.9; 95% CI, -18.8, 14.9, P = 0.823). The least square mean ± SE change in DAS28-CRP was -0.95 ± 0.16 for active stimulation and -0.66 ± 0.16 for sham (P = 0.201); in HAQ-DI it was -0.19 ± 0.06 for active stimulation and -0.02 ± 0.06 for sham (P = 0.044). Adverse events occurred in 17 patients (15%); all were mild or moderate. CONCLUSION: Auricular VNS did not meaningfully improve RA disease activity. If VNS with other modalities is pursued in the future for the treatment of RA, larger, controlled studies will be needed to understand its utility.
引用
- Baker MC, Kavanagh S, Cohen S, et al. A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis. Arthritis Rheumatol. 2023. PMID: 37390360. doi:10.1002/art.42637
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。